<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02549092</url>
  </required_header>
  <id_info>
    <org_study_id>M12-927</org_study_id>
    <secondary_id>2014-004865-26</secondary_id>
    <nct_id>NCT02549092</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)</brief_title>
  <official_title>An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to examine the effect of Levodopa-Carbidopa Intestinal
      Gel (LCIG) relative to that of OMT on non-motor symptoms associated with Parkinson's disease
      (PD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2015</start_date>
  <completion_date type="Anticipated">November 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Modified Parkinson's Disease Sleep Scale (PDSS-2) Total Score</measure>
    <time_frame>Week 0-26</time_frame>
    <description>Examine the effect of Levodopa-Carbidopa Intestinal Gel (LCIG) relative to that of Optimized Medical Treatment (OMT) on non-motor symptoms associated with advanced Parkinson's Disease (PD) as assessed by the Modified Parkinson's Disease Sleep Scale (PDSS-2) Total Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Non-Motor Symptoms Scale (NMSS) Total Score</measure>
    <time_frame>Week 0-26</time_frame>
    <description>Examine the effect of Levodopa-Carbidopa Intestinal Gel (LCIG) relative to that of Optimized Medical Treatment (OMT) on non-motor symptoms associated with advanced Parkinson's Disease (PD) as assessed by the Non-Motor Symptoms Scale (NMSS) Total Score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Week 0-26</time_frame>
    <description>The C-SSRS is a systematically administered instrument designed to assess suicidal behavior and ideation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>Week 0-26</time_frame>
    <description>ECGs will be recorded after laying down for at least 5 minutes and will be recorded while completely stationary, without talking, laughing, deep breathing or swallowing during the time of recording.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Global Impression of Change (PGIC) Score</measure>
    <time_frame>Week 0-26</time_frame>
    <description>7-point response scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Impulsive Disorders Interview (MIDI)</measure>
    <time_frame>Week 0-26</time_frame>
    <description>The MIDI is used to monitor for development of intense impulsive behavior.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Week 0-26</time_frame>
    <description>All negative changes in health during the study will be treated and recorded during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in King's PD Pain Scale Score</measure>
    <time_frame>Week 0-26</time_frame>
    <description>Clinical PD specific pain scale developed with a focus on sub classification of nociceptive pain and neuropathic pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Geriatric Depression Scale (GDS-15) Score</measure>
    <time_frame>Week 0-26</time_frame>
    <description>A short, self-report reliable and valid screening instrument for depression in the elderly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression of Change (CGI-C) Score</measure>
    <time_frame>Week 0-26</time_frame>
    <description>Clinician's rating scale for assessing Global Improvement or Change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Score</measure>
    <time_frame>Week 0-26</time_frame>
    <description>An investigator-used rating tool to follow the longitudinal course of Parkinson's disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sleep Attack Questionnaire (SAQ) Score</measure>
    <time_frame>Week 0-26</time_frame>
    <description>Assessment used to monitor for possible development of sleep attacks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mini-Mental State Examination (MMSE) Score</measure>
    <time_frame>Week 0-26</time_frame>
    <description>30 point questionnaire that provides a quantitative measure of cognitive mental status in adults</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Montreal Cognitive Assessment (MoCA) Score</measure>
    <time_frame>Week 0-26</time_frame>
    <description>Screening tool to assess mild cognitive impairment in the general population, often used in clinical settings to study cognition in PD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Parkinson's Anxiety Scale (PAS) Score</measure>
    <time_frame>Week 0-26</time_frame>
    <description>Scale developed specifically to measure severity in anxiety in Parkinson's Disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Parkinson's Disease Questionnaire (PDQ-8) Score</measure>
    <time_frame>Week 0-26</time_frame>
    <description>Disease-specific instrument designed to measure aspects of health that are relevant to subjects with PD, and which may not be included in general health status questionnaires.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Advanced Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Optimized Medical Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>26 Week Period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-SLV187</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>26 Week Period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-SLV187</intervention_name>
    <description>Dose levels will be individually optimized.</description>
    <arm_group_label>ABT-SLV187</arm_group_label>
    <arm_group_label>Optimized Medical Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant(s) must have a diagnosis of idiopathic Parkinson's disease according to
             the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria.

          2. Participant(s) demonstrates persistent motor fluctuations in spite of individually
             optimized treatment.

          3. The participant's Parkinson's disease is levodopa-responsive.

          4. Participant(s) has had optimized treatment with available anti-PD medication and their
             motor symptoms are judged inadequately controlled on this optimized treatment.
             Optimized treatment is defined as the maximum therapeutic effect obtained with
             pharmacological antiparkinsonian therapies when no further improvement is expected
             regardless of any additional manipulations of levodopa and/or other antiparkinsonian
             medication. This will be based on the Investigator's clinical judgment.

          5. Male or female participant(s) must be at least 30 years of age.

        Exclusion Criteria:

          1. Participant's PD diagnosis is unclear or there is a suspicion that the subject has a
             parkinsonian syndrome such as secondary parkinsonism (e.g. caused by drugs, toxins,
             infectious agents, vascular disease, trauma, brain neoplasm), parkinson-plus syndrome
             (e.g. Multiple System Atrophy, Progressive supranuclear Palsy, Diffuse Lewy Body
             disease) or other neurodegenerative disease that might mimic the symptoms of PD.

          2. Participant(s) has undergone neurosurgery for the treatment of Parkinson's disease.

          3. Known hypersensitivity to levodopa, carbidopa or radiopaque material.

          4. Participant(s) has contraindications to levodopa (e.g. narrow angle glaucoma,
             malignant melanoma).

          5. Participant(s) experiencing clinically significant sleep attacks or clinically
             significant impulsive behavior (e.g. pathological gambling, hypersexuality) at any
             point during the three months prior to the Screening evaluation as judged by the
             Principal Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Parkinson's and Movement</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boca Raton Regional Hospital</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida Neurology</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease Treatment</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Luke's Health System</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Movement Disorder Clinic</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Texas Neurology Consul</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Neurological, PLLC</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Goulburn Valley Hospital</name>
      <address>
        <city>Shepparton</city>
        <state>Victoria</state>
        <zip>3630</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Maria della Miseri</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Locale di</name>
      <address>
        <city>Ponderano,biella</city>
        <zip>13875</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Univ. Ospedali Riuniti</name>
      <address>
        <city>Torette</city>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>송파구</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>종로구</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Campus de la Salud</name>
      <address>
        <city>Granada</city>
        <zip>18016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Uni Insular de GC</name>
      <address>
        <city>Las Palmas</city>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Univ Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska Univ Sjukhuset</name>
      <address>
        <city>Solna</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2015</study_first_submitted>
  <study_first_submitted_qc>September 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>levodopa-carbidopa intestinal gel</keyword>
  <keyword>levodopa</keyword>
  <keyword>carbidopa</keyword>
  <keyword>Advanced Parkinson's Disease</keyword>
  <keyword>Non-Motor Symptom Scale NMSS</keyword>
  <keyword>Parkinson's Disease Sleep Scale PDSS-2</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

